Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) and NLS Pharmaceutics (NASDAQ:NCEL – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.
Analyst Recommendations
This is a breakdown of recent ratings for Eupraxia Pharmaceuticals and NLS Pharmaceutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eupraxia Pharmaceuticals | 1 | 1 | 5 | 2 | 2.89 |
| NLS Pharmaceutics | 1 | 0 | 1 | 0 | 2.00 |
Eupraxia Pharmaceuticals presently has a consensus price target of $18.00, suggesting a potential upside of 181.25%. NLS Pharmaceutics has a consensus price target of $23.00, suggesting a potential upside of 559.03%. Given NLS Pharmaceutics’ higher probable upside, analysts plainly believe NLS Pharmaceutics is more favorable than Eupraxia Pharmaceuticals.
Volatility and Risk
Valuation & Earnings
This table compares Eupraxia Pharmaceuticals and NLS Pharmaceutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eupraxia Pharmaceuticals | N/A | N/A | -$38.58 million | ($1.05) | -6.10 |
| NLS Pharmaceutics | N/A | N/A | -$8.30 million | N/A | N/A |
Profitability
This table compares Eupraxia Pharmaceuticals and NLS Pharmaceutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eupraxia Pharmaceuticals | N/A | -87.56% | -51.20% |
| NLS Pharmaceutics | N/A | N/A | N/A |
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.
About NLS Pharmaceutics
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
